Lessons from EMA Audit Findings in Rare Disease Clinical Trials
Lessons from EMA Audit Findings in Rare Disease Clinical Trials Key Takeaways from EMA Audit Findings in Rare Disease Clinical Trials Introduction: Why Rare Disease Trials Face EMA Scrutiny Rare disease clinical trials present unique regulatory challenges due to small patient populations, complex trial designs, and ethical considerations. The European Medicines Agency (EMA) pays close…
Read More “Lessons from EMA Audit Findings in Rare Disease Clinical Trials” »